company background image
RIGL logo

Rigel Pharmaceuticals NasdaqGS:RIGL Stock Report

Last Price

US$0.93

Market Cap

US$159.2m

7D

1.9%

1Y

-32.0%

Updated

28 May, 2024

Data

Company Financials +

Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Stock Report

Market Cap: US$159.2m

RIGL Stock Overview

A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

RIGL fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rigel Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rigel Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.93
52 Week HighUS$1.77
52 Week LowUS$0.71
Beta1.06
1 Month Change-15.33%
3 Month Change-39.91%
1 Year Change-32.01%
3 Year Change-74.55%
5 Year Change-57.28%
Change since IPO-98.54%

Recent News & Updates

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Recent updates

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Rigel Pharmaceuticals: Why The Stock Is On A Run

Mar 21

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06
What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

Feb 01

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14
An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

Nov 30

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 02
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

Sep 06

It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year

May 12
It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year

Shareholder Returns

RIGLUS BiotechsUS Market
7D1.9%-1.9%-0.3%
1Y-32.0%7.4%25.6%

Return vs Industry: RIGL underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: RIGL underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is RIGL's price volatile compared to industry and market?
RIGL volatility
RIGL Average Weekly Movement8.3%
Biotechs Industry Average Movement11.2%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: RIGL's share price has been volatile over the past 3 months.

Volatility Over Time: RIGL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996147Raul Rodriguezwww.rigel.com

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.

Rigel Pharmaceuticals, Inc. Fundamentals Summary

How do Rigel Pharmaceuticals's earnings and revenue compare to its market cap?
RIGL fundamental statistics
Market capUS$159.18m
Earnings (TTM)-US$19.80m
Revenue (TTM)US$119.25m

1.4x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RIGL income statement (TTM)
RevenueUS$119.25m
Cost of RevenueUS$28.62m
Gross ProfitUS$90.63m
Other ExpensesUS$110.43m
Earnings-US$19.80m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin76.00%
Net Profit Margin-16.61%
Debt/Equity Ratio-317.9%

How did RIGL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.